Jiankuan registers Phase 3 trial of proximod in rheumatoid arthritis
The study, led by Jiankuan (Suzhou) Biotechnology Company Limited, plans to enroll 590 participants and begin on October 15, 2026. It is to evaluate different doses of proximod in moderate-to-severe active rheumatoid arthritis subjects with inadequate response or intolerance to bDMARDs and/or tsDMARDs.
Primary source
ClinicalTrials.gov registry record, October 2, 2026
A Study to Evaluate the Efficacy and Safety of Proximod in Patients With Rheumatoid Arthritis
Read the source: A Study to Evaluate the Efficacy and Safety of Proximod in Patients With Rheumatoid Arthritis clinicaltrials.gov
Machine-summarized from the source above; not independently reported. How we use automation